Plus therapeutics announces first patient dosed in respect-gbm phase 2b trial of rhenium (186re) obisbemeda for treatment of recurrent glioblastoma

Austin, texas, jan. 18, 2023 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the respect-gbm phase 2b dose expansion clinical trial evaluating rhenium (186re) obisbemeda for the treatment of recurrent glioblastoma (gbm).
PSTV Ratings Summary
PSTV Quant Ranking